Here is the design of a clinical trial:

Official Title: Can Personalized Diet Therapy Favourably Impact Disease Severity in Patients With Crohn's Disease

Included conditions:
- Crohn Disease

Study Armgroups:
- {'label': 'CD-TDI', 'type': 'OTHER', 'description': 'Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.', 'interventionNames': ['Other: Therapeutic diet Intervention']}
- {'label': 'Conventional management', 'type': 'NO_INTERVENTION', 'description': 'Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare'}

Interventions:
- {'type': 'OTHER', 'name': 'Therapeutic diet Intervention', 'description': 'The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1', 'armGroupLabels': ['CD-TDI']}

Primary Outcomes:
- {'measure': 'Fecal calprotectin: Change is being assessed.', 'description': '\\<250 ug/mg with at least 100ug/g decline from baseline. FCP is a test used to detect inflammation in the colon and is associated with disease activity and severity.', 'timeFrame': 'baseline, 7 and 13 weeks.'}
- {'measure': 'Harvey Bradshaw Index (HBI): Change is being assessed', 'description': 'HBI is a validated, non-invasive measure of disease activity captured through a symptom questionnaire and is a surrogate to endoscopic assessment to determine disease severity. HBI minimum value is "0" and maximum no limit. HBI \\< 5 is used in this study to indicate clinical remission. HBI\\> 16 means severe disease activity. Higher scores means worse outcomes. Based on experience with past recruitment for clinical trials, endoscopic assessment is not feasible due to access and patient acceptance.', 'timeFrame': 'baseline, 7 and 13 weeks.'}
- {'measure': 'Bowel wall thickness on sonographic findings and Fecal calprotectin: Change is being assessed.', 'description': 'For asymptomatic patients with active disease at the time of recruitment (HBI \\<5 ) a combined primary endpoint using both FCP \\<250 ug/mg with at least 100ug/g decline from baseline and ultrasound findings of bowel wall thickening will be used.( ≤ 3mm).', 'timeFrame': 'baseline, 7 and 13 weeks for fecal calprotectin and baseline and week 13 for sonographic findings'}

Please estimate the sample size based on the assumption: 
Alpha level of 0.05, power of 0.80, 2:1 allocation ratio (CD-TDI to CM), 10% dropout rate
Sample size
        The sample size calculation is based on the primary outcome of symptomatic (clinical) and objective (biochemical) remission. We estimated the effect size estimates in the control group based on corticosteroid-free remission rates in the phase III CALM trial, wherein 23.8% (29/122) of patients in the conventional therapy arm achieved remission at week 11.39 Assuming a control group remission rate of 25%, an alpha level of 0.05, power of 0.80 and 2:1 allocation ratio (CD-TDI to CM), a sample size of 93 patients (62 and 31 patients randomised to CD-TDI and CM, respectively) would be sufficient to detect a remission rate 55% in the intervention arm. Estimates of the remission rate in the CD-TDI arm are based on a previous prospective trial of a similar dietary intervention in paediatric patients with mild-to-moderate CD.15 In this trial, 76% (28/37) of patients achieved clinical remission at week 12. Given that adding biochemical measures is likely to reduce the remission rate compared with symptoms alone and because paediatric patients may be more responsive to dietary interventions compared with adults, we used a more conservative estimate of remission in the CD-TDI arm of 55% for the power calculations. Assuming a 10% drop out rate, an estimated 102 patients must be randomised.